WednesdaySep 30, 2020 3:15 pm

Sufficient Vitamin D Levels May Reduce Coronavirus Complications, Death

Researchers have discovered that coronavirus patients who were hospitalized and had vitamin D sufficiency were at a significantly lower risk of experiencing hypoxia, becoming unconscious or dying. Additionally, they had high levels of lymphocytes, which are immune cells that help the body fight infections, and had low levels of the C-reactive protein, which is an inflammatory marker. The study was authored by Michael F. Holick, who is a professor of physiology, medicine and molecular medicine and biophysics at Boston University School of Medicine. The professor explained that the study provided evidence showing that sufficient levels of vitamin D reduced COVID-19…

Continue Reading

WednesdaySep 30, 2020 12:15 pm

Study Discovers That Septic Shock Begins Earlier than Scientists Thought

Researchers from Johns Hopkins University have discovered that septic shock can be classified into four categories, making it easier for hospitals to accurately triage sepsis patients and treat individuals who are at higher risk first. This will prevent a higher mortality rate from people dying due to this costly and deadly medical condition. The leading causes of in-hospital deaths are septic shock and sepsis. Biomedical researchers from the Johns Hopkins School of Medicine and Whiting School of Engineering state that their findings may be used to detect early signs of septic shock in patients who are rapidly developing the infection…

Continue Reading

TuesdaySep 29, 2020 2:30 pm

Study Uncovers Design Flaws in Symptom-Checking Apps

These days, millions of people go online to seek medical advice. Using chatbot symptom checker (“CSC”) apps, many share their symptoms and get potential diagnoses through the apps, all without having to visit a doctor. Compared to a trip to the doctor, are these apps better? According to a new study from Penn State’s College of Information Sciences and Technology, researchers discovered that CSC apps do not have the proper support system needed for the full diagnostic process like that of a traditional visit to your doctor. The apps support only about 5 processes of an actual doctor’s exam i.e.…

Continue Reading

TuesdaySep 29, 2020 1:29 pm

Predictive Oncology Inc. (NASDAQ: POAI) Set to Capitalize on Increased AI Usage within Oncological Treatments

Predictive Oncology develops AI-solutions designed to assist clinicians in formulating personalized treatment plans for oncological patients Artificial Intelligence is being increasingly used to help understand and accurately predict how drug therapies can interact with specific patients POAI’s TumorGenesis subsidiary is also creating laboratory-grown tumors to help clinicians and researchers to better test therapies Predictive Oncology (NASDAQ: POAI), a knowledge-driven precision medicine company that focuses on applying data and artificial intelligence (“AI”) to cancer personalized medicine and drug discovery, is set to play a key role as the integration of AI technology within cancer care continues to improve the accuracy and…

Continue Reading

TuesdaySep 29, 2020 12:37 pm

CNS Pharmaceuticals, Inc. (CNSP) Expands Scientific Advisory Board with Leading Neuro-Oncology Expert, Dr. Patrick Wen, M.D.

Pivotal Phase 2 Berubicin trial expected to commence in Q1 2021 following planned IND submission in Q4 2020 CNS Pharmaceuticals also plans to begin pre-clinical work on Berubicin in connection with treatment for lymphomas, pancreatic, and ovarian cancers Brain tumor drug therapeutics market expected to reach $3.4 billion by 2025 CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the central nervous system, has expanded its Scientific Advisory Board by welcoming new member Dr. Patrick Wen, M.D., a leading neurology and neuro-oncology expert (https://ibn.fm/VJ6e9). Dr. Wen joins current Board members,…

Continue Reading

TuesdaySep 29, 2020 10:45 am

Researchers Develop Simple Way to Detect Coronavirus Antibodies Using Glucose Monitors

Three scientists from Johns Hopkins; a biomedical engineer, a pharmacologist and a biophysicist, have come together to build a device that can detect if an individual has SARS-CoV-2 antibodies, which is the virus that causes COVID-19. Antibodies are small proteins produced by the immune system to help your body counteract a viral encounter and provide the immunity to fight it off if future infections occur. The researchers derived their inspiration from a glucose monitor, which is used by millions of people around the world. This, they said, could help them design an antibody detector that can be used easily and…

Continue Reading

MondaySep 28, 2020 2:45 pm

New AI Tool Can Quickly Spot Coronavirus Outbreaks in US Counties

Researchers from Georgia Tech, Harvard Medical School and the Boston Medical Center have developed a new online learning-based tool that allows the health sector to detect coronavirus outbreaks earlier in various counties in the U.S. The Coronavirus outbreak detection tool is usually updated 2-3 times every week. It forecasts how fast a coronavirus outbreak will spread in a county by approximating the doubling rate of cases. The doubling time refers to the total number of days it takes for the cases in any given county to double. The tool takes into consideration the reported coronavirus deaths and cases, social distancing…

Continue Reading

MondaySep 28, 2020 10:45 am

Wearable Device May Help EMTs Evaluate Hemorrhaging and Save Lives

Medical technicians, room physicians and military medics may be better equipped to treat victims of gunshot wounds, battlefield injuries and vehicular accidents thanks to a new device that is in the works. The device can evaluate the effects of hemorrhage on an individual. The research team currently working on the device development have demonstrated that the device could accurately evaluate blood loss through the measurement of seismic vibrations in an individuals’ thoracic cavity and also by detecting the changes in an individual’s heartbeat. Associate professor in the School of Electrical and Computer Engineering at the Georgia Institute of Technology, Omer…

Continue Reading

FridaySep 25, 2020 2:15 pm

Researchers Make Breakthrough Discovery That Could Transform Cancer Treatment

Recently, Professor Federica Sotgia and Professor Michael Lisanti made a discovery that could make cancer a treatable ailment. For many years, billions of dollars have been poured into the field of cancer research in an effort to find ways to treat and cure the disease. However, there are still no FDA/MHRA approved drugs that combat metastasis. As a result, cancer metastasis, which is lethal, remains an untreatable and mysterious disease. For those who may not be completely familiar with cancer metastasis; this is when cancer cells spread throughout the body’s organs such as the lungs, bone tissue, the brain and…

Continue Reading

FridaySep 25, 2020 1:15 pm

CNS Pharmaceuticals Inc. (NASDAQ: CNSP) is “One to Watch”

CNS Pharmaceuticals’ lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive and currently incurable form of brain cancer. In a Phase I clinical trial of Berubicin in malignant brain tumors, 44% of patients experienced a statistically significant improvement in clinical benefit. In preclinical studies, the company’s second drug candidate, a novel DNA binding agent, was 500-times more potent than the chemotherapeutic agent, daunorubicin, in inhibiting tumor cell proliferation. A global increase in neurological disorders has placed increased attention on cancers of the brain over the past decade. Industry reports estimate that the global brain…

Continue Reading

Official NewsWire Relationships

BIO Informa DGE Dynamic Global Events DTC Healthcare Conference Kiasco Reasearch Nexus Conferences Octane

BioMedWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 415.949.5050